PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.50
+4.97%Margins
Gross margin
82.9%
EBITDA margin
-14.7%
EBIT margin
-17.0%
Net margin
-41.3%
FCF margin
-15.3%
28.8%
Return on equity
-30.3%
Return on assets
22.9%
Return on invested capital
0.76x
Asset turnover
-$36.7M
Cash from operations
$2.26
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026